Company profile
UK company 09389592, incorporated on 15 January 2015.
Building functional in vitro models to improve clinical translation
Newcells Biotech are experts in building and applying functional in vitro models to improve clinical translation and drug discovery.
Company number 09389592
Updated 07 Jul 2026 09:49
Financial period: 1 Feb 2024 to 31 Jan 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Newcells Biotech develops stem cell technology that removes the need for embryonic stem cells, for use in modelling and drug discovery.
Newcells Biotech Ltd is a spin-out company from the Armstrong /Lako pluripotent stem cell research laboratories situated in the Institute of Genomic medicine, Newcastle University, Newcastle upon Tyne, UK. Its concept is to establish and commercialise model systems for efficacy and toxicity testing in drug discovery programmes within the pharmaceutical industry. Newcells Biotech offers a bespoke service for the generation of somatic cells derived from Induced Pluripotent Stem Cells created from tissue samples collected under informed consent from patients with a range of monogenetic and complex diseases. Prof. Lyle Armstrong, CSO has extensive experience in the generation, culture and differentiation of pluripotent stem cells. He is a founding member of Newcells Biotech Ltd where he is responsible for scientific oversight of research and development operations and strategic direction of the company.
The company was registered in January 2015, the first research contracts are in place and lab facility created.
the company is in the process of establishing business with several major pharmaceutical companies
1 May 2023 to 30 Apr 2026
1 Aug 2015 to 31 Jan 2016
Development of a new drug toxicity service and product offering for application the rapidly developing field of precision medicine.
